PUBLISHER: BCC Research | PRODUCT CODE: 1859699
PUBLISHER: BCC Research | PRODUCT CODE: 1859699
The global market for Artificial Intelligence (AI) in Clinical Trials was valued at $2 billion in 2024 and is estimated to increase from $2.4 billion in 2025 to reach $6.5 billion by 2030, at a compound annual growth rate (CAGR) of 22.6% from 2025 through 2030.
The North American market for AI in Clinical Trials was valued at $771.2 million in 2024 and is estimated to increase from $936.7 million in 2025 to reach $2.7 billion by 2030, at a CAGR of 23.7% from 2025 through 2030.
The Asia-Pacific market for AI in Clinical Trials was valued at $372.8 million in 2024 and is estimated to increase from $467.9 million in 2025 to reach $1.6 billion by 2030, at a CAGR of 28.4% from 2025 through 2030.
The report examines trends in the global market for AI in clinical trials. It segments the global market by component, phase, deployment mode, therapeutic area and end user. It also provides insights into key emerging trends and potential growth drivers. Components consist of software and services. Deployment mode include cloud, on-premise, and hybrid. Therapeutic areas include cancers, infectious diseases and neurological diseases. End users include pharmaceutical and biotech companies, contract research organizations (CROs), and research and academic institutes.
The report's regional analysis covers North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. It evaluates the impact of AI adoption in clinical trials and the market dynamics, including drivers and challenges. The study concludes with an analysis of leading companies in the market and their product portfolios.
It includes global revenue ($ millions) for the base year of 2024, estimates for 2025, and data for the forecast period of 2026 through 2030.